REAlease CD166-APC (REAL198) Kit, h，130-122-645，美天旎

Clone REAL198 is an antibody fragment derived from the full CD166 antibody molecule. It displays no binding to Fc receptors. The recombinantly engineered antibody fragments are multimerized to form the REAlease Complex to bind markers with high avidity.

Clone REAL198 recognizes the human CD166 antigen, a single-pass type I membrane protein also known as activated leukocyte cell adhesion molecule (ALCAM). CD166, a member of the immunoglobulin superfamily and a ligand for the lymphocyte antigen CD6, mediates homophilic and heterophilic adhesion. It is expressed on activated leukocytes T cells, B cells, monocytes, hematopoietic stem cells (HSCs), metastasizing melanoma, neuronal cells, endothelial cells, hematopoiesis-supporting osteoblastic cell lines, and MSCs. CD166 expression is pathologically correlated with aggressive disease in a variety of cancers including melanoma, prostate, breast, ovarian, esophageal, and bladder cancers. It is also a universal functional marker of murine and human hematopoietic stem cells (HSC) and osteoblasts within the hematopoietic niche and it is involved in modulating HSC-niche interactions and HSC fate.

The REAlease Kits consist of the respective fluorochrome-conjugated REAlease Complexes and the REAlease Support Kit for removal of the REAlease Complexes and optional relabeling with different fluorochrome-conjugated REAlease Complexes.

ALCAM, MEMD

Technical specifications